The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output
Abstract
CONTEXT: The only treatment available to restore normal cardiac output in patients with hereditary hemorrhagic telangiectasia (HHT) and cardiac failure is liver transplant. Anti-vascular endothelial growth factor treatments such as bevacizumab may be an effective treatment. OBJECTIVES: To test the efficacy of bevacizumab in reducing high cardiac output in severe hepatic forms of HHT and to assess improvement in epistaxis duration and quality of life. DESIGN, SETTING, AND PATIENTS: Single-center, phase 2 trial with national recruitment from the French HHT Network. Patients were 18 to 70 years old and had confirmed HHT, severe liver involvement, and a high cardiac index related to HHT. INTERVENTION: Bevacizumab, 5 mg per kg, every 14 days for a total of 6 injections. The total duration of the treatment was 2.5 months; patients were followed up for 6 months after the beginning of the treatment. MAIN OUTCOME MEASURE: Decrease in cardiac output at 3 months after the first injection, evaluated by echocardiography. RESULTS: A total of 25 patients were included between March 2009 and November 2010. Of the 24 patients who had echocardiograms available for reread, there was a response in 20 of 24 patients with normalization of cardiac index (complete response [CR]) in 3 of 24, partial response (PR) in 17 of 24, and no response in 4 cases. Median cardiac index at beginning of the treatment was 5.05 L/min/m(2) (range, 4.1-6.2) and significantly decreased at 3 months after the beginning of the treatment with a median cardiac index of 4.2 L/min/m(2) (range, 2.9-5.2; P < .001). Median cardiac index at 6 months was significantly lower than before treatment (4.1 L/min/m(2); range, 3.0-5.1). Among 23 patients with available data at 6 months, we observed CR in 5 cases, PR in 15 cases, and no response in 3 cases. Mean duration of epistaxis, which was 221 minutes per month (range, 0-947) at inclusion, had significantly decreased at 3 months (134 minutes; range, 0-656) and 6 months (43 minutes; range, 0-310) (P = .008). Quality of life had significantly improved. The most severe adverse events were 2 cases of grade 3 systemic hypertension, which were successfully treated. CONCLUSION: In this preliminary study of patients with HHT associated with severe hepatic vascular malformations and high cardiac output, administration of bevacizumab was associated with a decrease in cardiac output and reduced duration and number of episodes of epistaxis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00843440.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)
Shovlin, C. L., Guttmacher, A. E., Buscarini, E., Faughnan, M. E., Hyland, R. H., Westermann, C. J. J., Kjeldsen, A. D., & Plauchu, H. (2000) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(20000306)91:1<66::aid-ajmg12>3.0.co;2-p · Cited by 1,744
Self-citationMcAllister, K. A., Grogg, K. M., Johnson, D. W., Gallione, C. J., Baldwin, M. A., Jackson, C. E., Helmbold, E. A., Markel, D. S., McKinnon, W. C., Murrel, J., et al. (1994) · Nature Genetics · doi:10.1038/ng1294-345 · Cited by 1,482
Johnson, D. W., Berg, J. N., Baldwin, M. A., Gallione, C. J., Marondel, I., Yoon, S.-J., Stenzel, T. T., Speer, M., Pericak-Vance, M. A., Diamond, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0696-189 · Cited by 1,116
International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia
Faughnan, M. E., Palda, V. A., Garcia-Tsao, G., Geisthoff, U. W., McDonald, J., Proctor, D. D., Spears, J., Brown, D. H., Buscarini, E., Chesnutt, M. S., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmg.2009.069013 · Cited by 1,082
Self-citationKabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Gallione, C. J., Repetto, G. M., Legius, E., Rustgi, A. K., Schelley, S. L., Tejpar, S., Mitchell, G., Drouin, É., Westermann, C. J., & Marchuk, D. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15732-2 · Cited by 756
David, L., Mallet, C., Mazerbourg, S., Feige, J.-J., & Bailly, S. (2007) · Blood · doi:10.1182/blood-2006-07-034124 · Cited by 708
Self-citationKabbinavar, F. F., Hambleton, J., Mass, R. D., Hurwitz, H. I., Bergsland, E., & Sarkar, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.232 · Cited by 686
Gehan, E. A. (1961) · Journal of Chronic Diseases · doi:10.1016/0021-9681(61)90060-1 · Cited by 667
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Lu, J.-F., Bruno, R., Eppler, S., Novotny, W., Lum, B., & Gaudreault, J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0664-8 · Cited by 350
Liver involvement in hereditary hemorrhagic telangiectasia (HHT)
Garcia-Tsao, G. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.12.008 · Cited by 218
Lerut, J., Orlando, G., Adam, R., Sabb??, C., Pfitzmann, R., Klempnauer, J., Belghiti, J., Pirenne, J., Thevenot, T., Hillert, C., et al. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000247258.35406.a4 · Cited by 164
Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia
Mitchell, A., Adams, L. A., MacQuillan, G., Tibballs, J., vanden Driesen, R., & Delriviere, L. (2008) · Liver Transplantation · doi:10.1002/lt.21417 · Cited by 162
Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations
Buscarini, E., Plauchu, H., Garcia Tsao, G., White, R. I., Sabbà, C., Miller, F., Saurin, J. C., Pelage, J. P., Lesca, G., Marion, M. J., et al. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01340.x · Cited by 159
Self-citationFlieger, D., Hainke, S., & Fischbach, W. (2006) · Annals of Hematology · doi:10.1007/s00277-006-0147-8 · Cited by 121
Incidence and management of bevacizumab-related toxicities in colorectal cancer
Saif, M. W., & Mehra, R. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.4.553 · Cited by 111
Pasculli, G., Resta, F., Guastamacchia, E., Gennaro, L. D., Suppressa, P., & Sabbà, C. (2004) · Quality of Life Research · doi:10.1007/s11136-004-7865-y · Cited by 110
Buonamico, P., Suppressa, P., Lenato, G. M., Pasculli, G., D'Ovidio, F. D., Memeo, M., Scardapane, A., & Sabbà, C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.022 · Cited by 84
Nasal Septum Perforation in a Bevacizumab-Treated Patient with Metastatic Breast Cancer
Traina, T. A., Norton, L., Drucker, K., & Singh, B. (2006) · The Oncologist · doi:10.1634/theoncologist.11-10-1070 · Cited by 53
Bevacizumab-Induced Nasal Septum Perforation
Fakih, M., & Lombardo, J. C. (2006) · The Oncologist · doi:10.1634/theoncologist.11-1-85 · Cited by 47
An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics
Ternant, D., Cézé, N., Lecomte, T., Degenne, D., Duveau, A.-C., Watier, H., Dorval, E. D., & Paintaud, G. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181ef582a · Cited by 44
Self-citation
Cited by
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
EASL Clinical Practice Guidelines: Vascular diseases of the liver
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.040 · Cited by 808
Northup, P. G., Garcia‐Pagan, J. C., Garcia‐Tsao, G., Intagliata, N. M., Superina, R. A., Roberts, L. N., Lisman, T., & Valla, D. C. (2021) · Hepatology · doi:10.1002/hep.31646 · Cited by 667
Faughnan, M. E., Mager, J. J., Hetts, S. W., Palda, V. A., Lang-Robertson, K., Buscarini, E., Deslandres, E., Kasthuri, R. S., Lausman, A., Poetker, D., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1443 · Cited by 537
Self-citationBrain arteriovenous malformations
Lawton, M. T., Rutledge, W. C., Kim, H., Stapf, C., Whitehead, K. J., Li, D. Y., Krings, T., terBrugge, K., Kondziolka, D., Morgan, M. K., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.8 · Cited by 366
Metadata
- Authors
- Dupuis-Girod, S., Ginon, I., Saurin, J.-C., Marion, D., Guillot, E., Decullier, E., Roux, A., Carette, M.-F., Gilbert-Dussardier, B., Hatron, P.-Y., Lacombe, P., Lorcerie, B., Rivière, S., Corre, R., Giraud, S., Bailly, S., Paintaud, G., Ternant, D., Valette, P.-J., Plauchu, H., & Faure, F.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2012-03-07
- Volume
- 307
- Issue
- 9
- Pages
- 948-55
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2092559291
- Cited by
- 386
- References
- 23
- FWCI
- 12.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.